

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number 10/615,484

Filing Date July 8, 2003

First Named Inventor Fritzberg, Alan

Group Art Unit 1614 1614

Examiner Name Unknown D. Jones

Sheet 1 of 1

Attorney Docket No: 295.034US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
JD	2002/0176818 A1	11/28/2002	Fritzberg et al.	424	1.11	12/11/2001
	2003/0118508 A1	06/26/2003	Simon et al.	424	1.77	12/11/2002
	2003/0158393 A1	08/21/2003	Kasina	534	11	01/17/2003
	6,005,083 B1	12/21/1999	Kasina	534	10	03/28/1997
	6,177,551 B1	01/23/2001	Kasina	534	10	05/12/1999
	6,187,910 B1	02/13/2001	Kasina	534	10	05/12/1999
JD	6,528,627 B1	03/04/2003	Kasina	534	10	11/28/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date				
JD	WO 98/43678	10/08/1998				

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
--------------------	----------------------	---	----------------

EXAMINER

D. Jones

DATE CONSIDERED

7/20/04

Substitute Disclosure Statement Form (PTO-1448)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Espionage Reduction Act of 1950, no persons are required to respond to a solicitation of information unless it contains a valid OAS control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known Applicati n Number 10/615,484 Filing Date July 08, 2003 First Named Inventor Fritzberg, Alan Group Art Unit 1614-1616 Examiner Name Unknown D. Jones	
Sheet 1 of 10		Attorney Docket No: 295.034US1	

Class Subclass

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Date				Translation
D.J.	CA 1,078,731	06/03/1980				
	EP 0 164 843	12/18/1985				
	EP 0 210 043	01/28/1987				
	EP 0 232 751	08/19/1987				
	EP 0 255 471	02/03/1988				English Abstract
	EP 0 258 616	03/09/1988				
	EP 0 287 465	10/19/1988				English Abstract
	EP 0 374 501	06/27/1990				
	EP 0 382 582	08/16/1990				
	EP 0 408 701	01/23/1991				
	EP 0 411 941	02/06/1991				
	EP 0 455 380	11/06/1991				
	EP 0 698 029	02/28/1996				
	EP 0 972 528	01/19/2000				English Abstract
	FR 2 230 374	12/20/1974				English Abstract
	WO 84/03698	09/27/1984				
	WO 90/06776	06/28/1990				
	WO 91/16075	10/31/1991				
	WO 93/25240	12/23/1993				
	WO 94/26753	11/24/1994				
	WO 95/10940	04/27/1995				
	WO 00/76556	12/21/2000				
	WO 01/91806	12/06/2001				

EXAMINER

D. Jones

DATE CONSIDERED

7/20/04

Substitute Disclosure Statement Form (PTO-1449)


*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional): Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2003. OMB 0310-0001
US Patent & Trademark Office, U.S. DEPT. OF COMMERCE

Complete if Known

Application Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1614-1610
Examiner Name	Unknown Jones

Sheet 2 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.
1	"Bone Cancer Therapy Project Funding Awarded to Brookhaven National Laboratory for Diate-
2	Licensed Product", DISTRIBUTION: Business Editors and Health/Medical Writers (1999).
3	"Breast Cancer; Genitourinary Cancer; Multiple Myeloma", Annotated Guide to Cancer
4	Chemotherapeutic Regimens 1999/2000, Oncology Special Edition, 13-14; 17-18; 32.
5	"Chapter III: Chemotherapy Regimens in Adults", In Cancer Chemotherapy Pocket Guide,
6	Robert J. Ignoffo, Editor, 248-255; 338-341 (1998).
7	"Multiple Myeloma", In Clinical Oncology, A Multidisciplinary Approach for Physicians and
8	Students, 7th Edition, Philip Rubin, Editor, 239-244 (1993).
9	"NeoRx Updates Skeletal Targeted Radiotherapy (STR) Phase I/II Trial Data", NeoRx Press
10	Release, (2001).
11	"NeoRx's Multiple Myeloma Study with Targeted Radiotherapy to be Updated at ASH -- Recent
12	Thalidomide Results Heighten Interest in New Multiple Myeloma Therapies", NeoRx Press
13	Release, (1999).
14	"NeoRx's Targeted Radiotherapy Achieves Complete Responses with Excellent Safety in
15	Multiple Myeloma Patients", NeoRx Press Release, (1999).
16	"Phase I/II Interim Data on NeoRx's STR Product in Multiple Myeloma", NeoRx Press Release,
17	(1999).
18	ABRAMS, "High-Dose Targeted Radiation to Bone and Bone Metastases", CaP CURE Meeting,
19	Lake Tahoe, NV (2000).
20	ALEXANIAN et al., "Impact of Complete Remission with Intensive Therapy in Patients with
21	Responsive Multiple Myeloma", British Journal of Hematology, 27, 1037-1043 (2001).
22	ANDERSON et al., "High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate:
23	Low Toxicity of Skeletal Irradiation in Patients with Osteosarcoma and Bone Metastases",
24	Journal of Clinical Oncology, 20, 189-196 (2002).
25	ANDO et al., "177Lu-EDTMP: A Potential Therapeutic Bone Agent", Nucl. Med. Commun, 19,
26	587-591 (1998).
27	APPELBAUM et al., "Chronic and Acute Leukemias in Adults", The Role of Marrow
28	Transplantation in the Treatment of Leukemia, Martinus Nijhoff Publishers, Boston. C.D.
29	Bloomfield, editor, 229-262 (1985).
30	APPELBAUM et al., "Specific Marrow Ablation Before Marrow Transplantation Using an
31	Aminophosphonic Acid Conjugate 166Ho-EDTMP", Blood, 80, 1608-1613 (1992).
32	BARDIES et al., "Computational Methods in Radionuclide Dosimetry", Physics in Medicine and
33	Biology, 41, 1941-1955 (1996).
34	BARLOGIE et al., "Prognostic Factors with High-Dose Melphalan for Refractory Multiple
35	Myeloma.", Blood, 72, 2015-2019 (1988).
36	BATAILLE et al., "Multiple Myeloma", New England Journal of Medicine, 336, 1657-1664 (1997).
37	BAYOUTH et al., "Dosimetry Considerations of Bone-Seeking Radionuclides for Marrow
38	Ablation", Medical Physics, 20, 1089-1096 (1993).
39	BAYOUTH et al., "Pharmacokinetics, Dosimetry and Toxicity of Holmium-166-DOTMP for Bone
40	Marrow Ablation in Multiple Myeloma", The Journal of Nuclear Medicine, 36, 730-737 (1995).
41	BAYOUTH et al., "Radiation Dose Distribution Within the Bone Marrow of Patients Receiving
42	Holmium-166-Labeled-Phosphonate for Marrow Ablation", Medical Physics, 22, 743-753 (1995).

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw the through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional): Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

PTO/USPOA(10-01)
Approved for use through 10/31/2002. OMB 051-0031
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1614-1666
Examiner Name	Unknown Jones

Sheet 3 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DA	BEARMAN et al., "Regimen-related Toxicity in Patients Undergoing Bone Marrow Transplantation", <u>Journal of Clinical Oncology</u> , 6 , 1562-1568 (1988).
	BEDDOE et al., "Measurements of Trabecular Bone Structure in Man", <u>Physics in Medicine and Biology</u> , 21 , 589-607 (1976).
	BENSINGER et al., "166Holmium-DOTMP Plus Standard High Dose Chemotherapy (HDC) with Autologous Transplant Produce High Rates of Complete Remission (CR) in Multiple Myeloma (MM) Patients: An Updated Report of a Phase I/II Study", <u>Proceedings of the American Society of Clinical Oncology</u> , 20 , Abstract No. 18, 5a (2001).
	BENSINGER et al., "Phase I/II Study of 166Holmium-DOTMP in Combination with Melphalan +/- Total Body Irradiation (TBI) with Autologous Peripheral Blood Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>Proceedings of the American Society of Clinical Oncology</u> 2000 , 19 , Abstract No. 26, 9a (2000).
	BENSINGER et al., "166Ho-DOTMP and High-Dose Melphalan before Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma", Abstract P287; IXth International Workshop on Multiple Myeloma (2003).
	BENSINGER et al., "Skeletal Targeted Radiotherapy (STR) with 166Ho-DOTMP plus Melphalan and Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma(MM)", <u>Meeting Proceedings of ASCO</u> , 22 , ASCO Annual Meeting, May 2003; Abstract Number 3346, 833 (2003).
	BIGLER et al., "Skeletal Distribution of Mineralized Bone Tissue in Humans", <u>Health Physics</u> , 31 , 213-218 (1976).
	BOUSSIOTIS et al., "Bone Marrow Transplantation for Low-grade Lymphoma and Chronic Lymphocytic Leukemia", <u>Semin Hematol</u> , 36 , 209-216 (1999).
	BREITZ, "Dosimetry in a Myeloablative Setting", Annual Society of Nuclear Medicine Meeting, Continuing Education Course (2001).
	BREITZ et al., "Dosimetry in Myeloablative Setting", <u>Cancer Biother. Radiopharm.</u> , 17 , 119-128 (2002).
	BREITZ et al., "Dosimetry of High Dose Skeletal Targeted Radiotherapy with Ho-166 DOTMP", Presentation at VIIth International Radiopharmaceutical Dosimetry Symposium (2002).
	BREITZ et al., "Multiple Myeloma: Skeletal Targeted Radiotherapy with 166-Ho-DOTMP for Treatment of Multiple Myeloma", Presented at "Targeted Radionuclide Therapy" (2002).
	BREITZ, "Quantitative Dosimetry Workup in a Myeloablative Setting", Presentation at the 48th Annual Society for Nuclear Medicine Meeting (2001).
	BREITZ et al., "Dosimetry of High Dose Skeletal Targeted Radiotherapy (STR) with 166-Ho-DOTMP", <u>Cancer Biotherapy and Radiopharmaceuticals</u> , 18 , 225-230 (2003).
	CHAMPLIN et al., "166Holmium-DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen for Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM)", <u>Blood</u> , 94 (10), American Society of Hematology, Abstract No. 3133, 709a (1999).
DA	CHAMPLIN et al., "Bone Marrow Transplantation for Acute Leukemia: Recent Advances and Comparison with Alternative Therapies", <u>Seminars in Hematology</u> , 24 , 55-67 (1987).

EXAMINER

[Signature]

DATE CONSIDERED

7/20/04

Substitute Disclosure Statement Form (PTO-1449)
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional): Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Complete if Known

Application Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1614 1416
Examiner Name	Unknown D Jones

Sheet 4 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.
79	CHAMPLIN et al., "Holmium-166 DOTMP, A Bone Seeking Radiochelate for Selective Marrow Radiotherapy with Bone Marrow Transplantation (BMT) for Multiple Myeloma", <u>Experimental Hematology</u> , 21, Abstracts, 22nd Annual Meeting of the International Society for Experimental Hematology, Rotterdam, The Netherlands, Abstract No. 393, 1117 (1993).
	CHAMPLIN et al., "Holmium-166 DOTMP, A Bone Seeking Radiochelate For Selective Marrow Radiotherapy with Bone Marrow Transplantation (BMT) for Multiple Myeloma", <u>Blood</u> , 82, Abstracts, American Society of Hematology Thirty-Fifth Annual Meeting, St. Louis, MO, Abstract No. 1051, 266a (1993).
	CHAMPLIN et al., "Phase I/II Study of Targeted Radiotherapy Using 166Ho-DOTMP with Melphalan and Peripheral Blood Stem Cell Transplant for Multiple Myeloma", A slide presentation, International Society of Experimental Hematology (2000).
	CHAMPLIN et al., "Role of Bone Marrow Transplantation in the Treatment of Hematologic Malignancies and Solid Tumors: Critical Review of Syngeneic, Autologous, and Allogeneic Transplants.", <u>Cancer Treatment Reports</u> , 68, 145-161 (1984).
	CHAMPLIN, R., et al., "Two Phase I/II Studies of 166Holmium-DOTMP in Combination with Melphalan With or Without Total Body Irradiation as a Preparative Regimen for Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>Experimental Hematology</u> , 27(7), Abstract No. 196, Program and Abstracts, 28th Annual Meeting of the International Society for Experimental Hematology, Monte Carlo, Monaco, 88 (1999).
	CLEYNHENS et al., ^{99m} Tc-EC-AMDP, a Bone Agent with Rapid Clearance from Soft Tissue", <u>Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine</u> , 5, 605-609 (1999).
	COHEN et al., "Bisphosphonates and Tetracycline: Experimental Models for Their Evaluation in Calcium-Related Disorders", <u>Pharmaceutical Research</u> , 15, 606-613 (1998).
	CUNNINGHAM et al., "High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data", <u>Journal of Clinical Oncology</u> , 12, 764-768 (1994).
	DISPENZIERI et al., "A Phase I Study of a Conditioning Regimen for Peripheral Stem Cell Transplantation (PBSCT) for Multiple Myeloma (MM): 153Samarium Ethylenediaminetetramethylenephosphonate (153SM-EDMPT) and Melphalan", <u>Blood</u> , 96, Abstract 2397, 558a (2000).
	DISPENZIERI et al., "A Phase I/II Dose Escalation Study of 153-Samarium EDTMP (153-Sm-EDMTP) with Fixed Dose Melphalan Peripheral Stem Cell Transplantation (PBSCT) for Multiple Myeloma (MM)", <u>Blood</u> , 98, Abstract 2855, 682a-683a (2001).
	DURRANT et al., "Sm-153 Lexidronam, Limb Irradiation and Stem Cell Transplantation for the Treatment of Multiple Myeloma", <u>Amer. Soc. Hematology Annual Meeting</u> , Orlando, FL. (2001).
	EARY et al., "Samarium-153-EDTMP Biodistribution and Dosimetry Estimation", <u>The Journal of Nuclear Medicine</u> , 34, 1031-1036 (1993).
	ECKERMAN et al., "Dose Conversion Factors for Marrow and Bone by Skeletal Regions", <u>Journal of Nuclear Medicine</u> , 35, 112P (1994).
79	EISENHUT, M., "Iodine-131-Labeled Diphosphonates for the Palliative Treatment of Bone Metastases: I. Organ Distribution and Kinetics of I-131 BDP3 in Rats", <u>The Journal of Nuclear Medicine</u> , 25, 1356-1361 (1984).

EXAMINER

[Signature]

DATE CONSIDERED


7/20/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw the through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) is Applicant to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Sheet 5 of 10

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

PTO-52/03A (10-01)
Approved for use through 10/01/2002. OMB #3165-0031
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known

Applicant Number	10/615,484
Filing Date	July 08, 2003
Fir t Named Inv nt r	Fritzberg, Alan
Group Art Unit	1614 / 616
Examiner Name	Unknown D. Jones

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
AK	EISENHUT et al., "The Influence of Substituents in ^{99m} Tc-Benzylidenediphosphonate Complexes on their Organ Distribution in Rats", <u>Nuklearmedizin</u> , 23 , 119-122 (1984).
	FIRUSIAN et al., "Results of 89Strontium Therapy in Patients with Carcinoma of the Prostate and Incurable Pain from Bone Metastases: A Preliminary Report", <u>The Journal of Urology</u> , 116 , 764-768 (1976).
	FRITZBERG, "Holmium-166 DOTMP for Marrow Ablation: Clinical Studies to Demonstrate Efficacy in Multiple Myeloma", Society of Nuclear Medicine Annual Meeting, St. Louis (2000).
	FUJISAKI et al., "Physicochemical Characterization of Bisphosphonic Carboxyfluorescein for Osteotropic Drug Delivery", <u>J Pharm Pharmacol.</u> , 48 , 798-800 (1996).
	GARLICH et al., "Chemical Considerations of 153Sm-EDTMP, a New Therapeutic Bone Agent", Sixth International Symposium on Radiopharmaceutical Chemistry: Abstracts. Boston, June 29-July 3, 1986. Paper 140, 317-319 (1986).
	GARLICH et al., "Chemistry of Novel Macrocyclic Aminophosphonic Acid Chelates of Rare Earth Radionuclides and Their in vivo Biodistribution", <u>The Journal of Nuclear Medicine</u> , 34 , Abstract Book, Proceedings of the 40th Annual Meeting, Toronto, Ontario, Canada, Abstract No. 1134, 244P (1993).
	GERALDES et al., "Synthesis, Protonation Sequence, and NMR Studies of Polyazamacrocyclic Methylene phosphonates", <u>Inorganic Chemistry</u> , 28 , 3336-3341 (1989).
	GIRALT et al., "Hemorrhagic Cystitis after Targeted Radiotherapy with Holmium-DOTMP (166Ho) for Multiple Myeloma (MM) is Preventable with Bladder Irrigation", <u>Blood</u> , 96 (11), Abstract No. 1686 (2000).
	GIRALT et al., "Preliminary Results of a Phase I/II Study of Multiple Myeloma (MM) Patients Treated with 166Holmium-DOTMP in Combination with High Dose Melphalan +/- Total Body Irradiation (TBI) with Autologous Stem Cell Transplant (ASCT)", <u>Blood</u> , 96 (11), Abstract No. 2395 (2000).
	GIRALT et al., "Results of a Phase I/II Trial with 166Ho-DOTMP Plus High Dose Chemotherapy in Patients with Multiple Myeloma", <u>VIIIth Int'l Multiple Myeloma Proceedings</u> , Abstract No. S24, 40-41 (2001).
	GIRALT et al., "Two Phase I/II Studies of 166Holmium-DOTMP in Combination with or without TBI as a Preparative Regimen for Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma", <u>VIIth Int'l Multiple Myeloma Workshop</u> , Abstract No. 033, Meeting Held September 1-5, 1999, 117 (1999).
	GIRALT et al., "166Ho-DOTMP Plus Melphalan Followed by Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma: Results of Two Phase I/II Trials", <u>Blood</u> , Blood First Edition Paper; DOI 10.1182/2002-10-3250, 1-38 (2003).
	GIRALT et al., "Long-Term Follow-Up of 83 Patients with Multiple Myeloma (MM) Treated on a Phase I-II Study of Skeletal Targeted Radiotherapy (STR) Using 166Ho-DOTMP Plus Melphalan with or without Total Body Irradiation (TBI) and Autologous Hematopoietic Stem Cell ...", <u>Blood</u> , 100 , 44th Annual Meeting of the American Society of Hematology; Abstract 670, 179a (2002).
AK	GOECKELER et al., "Samarium-153 Radiotherapeutic Bone Agents", <u>Nucl. Med. Biol.</u> , 13 , 479-482 (1986).

EXAMINER

D. Jones

DATE CONSIDERED

7/20/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 800. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Sheet 6 of 10

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2003. OMB 6010-0001
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known

Applicant Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1614 1614
Examiner Name	Unknown D. Jones

Attorney Docket No: 295.034US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DO	HASSFJELL et al., "212Bi-DOTMP: An Alpha Particle Emitting Bone-Seeking Agent for Targeted Radiotherapy", <u>Nuclear Medicine and Biology</u> , 24, 231-237 (1997).
	HOGAN et al., "Successful Treatment of POEMS Syndrome with Autologous Hematopoietic Progenitor Cell Transplantation", <u>Bone Marrow Transplantation</u> , 28, 305-309 (2001).
	HSIA et al., "Preparation of 113mIn-DTPMP Bone Scanning Agent and its Preliminary Clinical Application", <u>Chemical Abstracts</u> , 95, 305 (1981).
	JARVIS et al., "Characterization of the Bisphosphonate Recognition Site on Hydroxyapatite Using Radioligand Binding Techniques with [¹⁴ C]Citric Acid", <u>Calcif Tissue Int.</u> , 52, 372-377 (1993).
	JOHN et al., "Formulation Development and Stability of the 166Ho-DOTMP for High Level Dosages - A Skeletal Targeted Radiotherapeutic", <u>Journal of Nuclear Medicine</u> , 42, Proceedings of the SNM 48th Annual Meeting, No. 1122, 267P (2001).
	KABACHNIK et al., "Synthesis and Acid-Base and Complex-Forming Properties of 1,4,7,10 - Tetrakis (dihydroxyphosphorylmethyl) - 1,4,7,10 - tetraazacyclododecane", <u>Bulletin of the Academy of Sciences of the USSR: Division of Chemical Science</u> , 33, 777-782 (1984).
	KABACHNIK et al., "Synthesis and Study of a New Complexone - N,N',N'' - Tris-(Dihydroxyphosphorylmethyl) - 1,4,7 - Triazacyclononane", <u>Bulletin of the Academy of Sciences of the USSR: Division of Chemical Science</u> , 33, 769-777 (1984).
	KAPLAN et al., "Therapy of Carcinoma of the Prostate Metastatic to Bone with P32 Labeled Condensed Phosphate", <u>The Journal of Nuclear Medicine</u> , 1, 1-13 (1980).
	KASI et al., "Ho-166DOTMP: A New Agent for Bone Marrow Ablation", <u>The Journal of Nuclear Medicine</u> , 34, Abstract Book, Proceedings of the 40th Annual Meeting, Toronto, Ontario, Canada, Abstract No. 125, 33P (1993).
	KEELING et al., "Yttrium-90-EDTMP: A Radiotherapeutic Agent in the Treatment of Leukaemias", <u>British Journal of Cancer</u> , 60, 74-78 (1989).
	KETRING, "153Sm-EDTMP and 186Re-HEDP as Bone Therapeutic Radiopharmaceuticals", <u>Nucl. Med. Biol.</u> , 14(3), 223-232 (1987).
	KOHN, "The Current Status of Gene Therapy Using Hematopoietic Stem Cells", <u>Current Opinion in Pediatr.</u> , 7, 56-63 (1995).
	KOTHARI et al., "186Re and 188Re Phosphonate Ligands", <u>The Journal of Nuclear Medicine</u> , 40, Proceedings of the 46th Annual Meeting, Abstract No. 1015, 228P (1999).
	KRISHNAMURTHY et al., "Tin-117m(4+)DTPA: Pharmacokinetics and Imaging Characteristics in Patients with Metastatic Bone Pain", <u>The Journal of Nuclear Medicine</u> , 38, 230-237 (1997).
	KRIVIT et al., "Bone Marrow Transplantation as Effective Treatment of Central Nervous System Disease in Globoid Cell Leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and ...", <u>Curr Opin Neurol</u> , 12(2), 167-176 (1999).
	LARSEN et al., "Preliminary Evaluation of a New Radiolabelled Bisphosphonate", <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , XLI, 823-830 (1998).
	LOGAN et al., "Radiation Dose Calculations in Persons Receiving Injection of Samarium-153-EDTMP", <u>J. Nucl. Med.</u> , 28, 505-509 (1987).

EXAMINER

D. Jones

DATE CONSIDERED

7/20/04


Substitute Disclosure Statement Form (PTO-1449)
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08(10-01)
Approved for use through 12/31/2002. GPO: 2002-0-0031
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number 10/615,484

Filing Date July 08, 2003

First Named Inventor Fritzberg, Alan

Group Art Unit 4614-1614

Examiner Name Unknown D Jones

Sheet 7 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
MA	MA et al., "Indium-113m Labeled Bone Imaging Agents - Animal Experiment and Clinical Application of 113mIn-DTPMP and 113mIn-EDTMP", <u>Chemical Abstracts</u> , 93, 285 (1980).
	MATHIEU et al., "Preparation of Rhenium-186 Labelled EHDP and its Possible Use in the Treatment of Osseous Neoplasms", <u>International Journal of Applied Radiation and Isotopes</u> , 30, 725-727 (1979).
	MCCULLOUGH et al., "99mTc-MDP as a Surrogate Quantitative Imaging Agent for High Dose 166Ho-DOTMP Bone Marrow Ablation Therapy", <u>Society of Nuclear Medicine Proceedings of the 47th Annual Meeting</u> , 41(5), 147P (2000).
	MCCULLOUGH et al., "Non-target Organ Doses in Patients Undergoing Bone Marrow Ablation with Ho-166-DOTMP", <u>The Journal of Nuclear Medicine</u> , 39, No. 5, Abstract Book, Scientific Abstracts of the 45th Annual Meeting of the Society of Nuclear Medicine, Toronto, Ontario, Canada, Abstract No. 838, 186P (1998).
	MCCULLOUGH et al., "Pharmacokinetics and Patient Specific Dosimetry of High Dose 166Ho-DOTMP Therapy Used for Treatment of Breast Cancer Metastatic to Bone", <u>The Journal of Nuclear Medicine: Proceedings of the 46th Annual Meeting</u> , 40, 40P (1999).
	MCCULLOUGH et al., "Preliminary Correlation of Bone Marrow Dose Distributions and Disease Response in Multiple Myeloma Patients Treated with Target Skeletal Radiotherapy", <u>The Journal of Nuclear Medicine, Proceedings of the 47th Annual Meeting</u> , 41(5), Abstract No. 327, 83P (2000).
	MOREAU et al., "Melphalan 220 mg/m2 Followed by Peripheral Blood Stem Cell Transplantation in 27 Patients with Advanced Multiple Myeloma", <u>Bone Marrow Transplant</u> , 23(10), 1003-1006 (1999).
	NAIL, "The Relationship Between the Structure of Aluminum Hydride Gel and Acid Reactivity", <u>Chemical Abstracts</u> , 84, 353 (1976).
	O'MARA et al., "Rare Earth Nuclides as Potential Agents for Skeletal Imaging", <u>The Journal of Nuclear Medicine</u> , 10, 49-51 (1969).
	PARKS et al., "Bone Marrow Transplantation in Dogs After Radio-Ablation with a New Ho-166 Amino Phosphonic Acid Bone-Seeking Agent (DOTMP)", <u>Blood</u> , 82(1), 318-325 (1993).
	PAULSON, "Seattle Leads in Stem Cell Study: Fred Hutchinson Team Explores Options with Autoimmune Project", <u>The Seattle Post-Intelligencer</u> , (1999).
	PODOLOFF et al., "Phase I/II Studies of Holmium-166 DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen For Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma (MM)", <u>European Journal of Nuclear Medicine</u> , Abstract No. PS-641, 1213. (date not available)
	PODOLOFF et al., "Phase I/II Study of Holmium-166-DOTMP for Bone Marrow Ablation in Multiple Myeloma Prior to Bone Marrow Transplantation (BMT)", <u>The Journal of Nuclear Medicine</u> , 35, Abstract Book, Proceedings of the 41st Annual Meeting, Orlando, FL, Abstract No. 139, 37P (1994).
	PODOLOFF, "The Role of Radiolabeled Isotopes and the Treatment of Solid Tumors", <u>Accomplishments with Medical Isotopes: Advanced Health Care for the 21st Century</u> , Medical Isotopes and the 21st Century (1999).


EXAMINER

DATE CONSIDERED

2/20/04

Substitute Disclosure Statement Form (PTO-1449)
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) is Applicant's to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it carries a valid OMB control number.

PTO/SB/CIA (10-01)
 Approved for use through 10/31/2002. OMB 0314-0031
 US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known	
Application Number	10/615,484
Filing Date	July 08, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	4614-1616
Examiner Name	Unknown <i>D. Jones</i>

Sheet 8 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>RG</i>	PODOLOFF et al., "Update on the Ho-166 DOTMP Bone Marrow Ablation Trial at U.T.M.D. Anderson Cancer Center", <u>Journal of Nuclear Medicine</u> , 37, Supplement: Radiolabeled IUDr, Abstract No.1053, 234P (1996).
	RAJENDRAN et al., "High Dose Holmium-166 DOTMP Myeloablative Treatment for Multiple Myeloma", <u>Journal of Nuclear Medicine</u> , Proceedings of the 47th Annual Meeting, 146P (2000).
	RAJENDRAN et al., "Holmium-166 DOTMP: An Agent with Ideal Physical and Pharmacokinetic Characteristics for Use in Myeloablative Treatment of Multiple Myeloma", <u>Western Regional Soc. Nucl. Med.</u> (2000).
	RAJENDRAN et al., "High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation", <u>J Nucl Med</u> , 43, 1383-1390 (2002).
	ROSCH et al., "Radiation Doses of Yttrium-90 Citrate and Yttrium-90 EDTMP as Determined via Analogous Yttrium-86 Complexes and Positron Emission Tomography", <u>European Journal of Nuclear Medicine</u> , 23, 958-966 (1996).
	ROSOFF et al., "Distribution and Excretion of Radioactive Rare-Earth Compounds in Mice", <u>International Journal of Applied Radiation and Isotopes</u> , 14, 129-135 (1962).
	SALTUS, "Double Transplant's Success May Lead to End of Rejection Drugs", <u>The Seattle Post-Intelligencer</u> , (1999).
	SCHMIDT et al., "89-Sr for the Treatment of Incurable Pain in Patient with Neoplastic Osseous Infiltrations", <u>Int. J. Clin. Pharmacol.</u> , 9, 199-205 (1974).
	SHERRY, "31P and 23Na NMR Lanthanide Induced Shifts in Axially Symmetric Macrocyclic Phosphonate Complexes", <u>Inorganica Chimica Acta</u> , 139, 137-139 (1987).
	SHERRY et al., "Dy(DOTP)5-: A New, Stable, 23Na Shift Reagent", <u>Journal of Magnetic Resonance</u> , 76, 528-533 (1988).
	SHIBATA et al., "Selectively Eliminated Blood Monocytes and Splenic Suppressor Macrophages in Mice Depleted of Bone Marrow by Strontium 89", <u>J. Leukocyte Biol.</u> , 38, 659-669 (1985).
	SIMON et al., "153Sm-EDTMP, a Potential Therapeutic Bone Agent", Sixth International Symposium on Radiopharmaceutical Chemistry: Abstracts. Boston, June 29-July 3, 1986. Paper 141, 320-322 (1986).
<i>RG</i>	SPIERS et al., "Mean Skeletal Dose Factors for Beta-particle Emitters in Human Bone. Part II: Surface-seeking Radionuclides", <u>British Journal of Radiology</u> , 54, 500-504 (1981).
<i>RG</i>	SRIVASTAVA et al., "10Ruthenium-97 Labeled Compounds - A New Class of Radiopharmaceuticals", <u>Medical Department, Brookhaven National Laboratory</u> , Upton, NY 11973, 123-133. (year not available)
<i>RG</i>	STABIN et al., "Bremsstrahlung Radiation Dose in Yttrium-90 Therapy Applications", <u>J Nucl Med</u> , 35, 1377-1380 (1994).
<i>RG</i>	SUBRAMANIAN et al., "Indium-113m Labeled Polyfunctional Phosphonates as Bone Imaging Agents", <u>Chemical Abstracts</u> , 87, 243 (1977).
<i>RG</i>	SUBRAMANIAN et al., "Indium-113m-Labeled Polyfunctional Phosphonates as Bone-Imaging Agents", <u>Journal of Nuclear Medicine</u> , 16, 1080-1084 (1975).

EXAMINER

D. Jones

DATE CONSIDERED


7/20/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 800. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

PTO-2200A(10-01)
Approved for use through 10/31/2002, OMB 031-0031
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known

Applicat n Numb r	10/615,484
Filing Dat	July 08, 2003
First Named Invent r	Fritzberg, Alan
Group Art Unit	1614-1616
Examiner Name	Unknown D. Jones

Sheet 9 of 10

Attorney Docket No: 295.034US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
RG	SUBRAMANIAN et al., "Localization of new Tc-99m Labeled Diphosphonates in Experimental Bone Lesions", Presented at the 19th International Annual Meeting of the Society of Nuclear Medicine Europe, Bern, Switzerland, September 8-11, 1981 (1981).
	SWAILEM et al., "In vivo Tissue Uptake and Retention of Sn-117m(4+)DTPA in a Human Subject with Metastatic Bone Pain and in Normal Mice", <u>Nuclear Medicine & Biology</u> , 25, 279-287 (1988).
	TANANAEV et al., "Lanthanide Ethylenediametetramethylphosphonates", <u>Chemical Abstracts</u> , 96, 553 (1982).
	THOMAS, "Clinical Trials with Bone Marrow Transplantation", <u>Clinical Trials in Cancer Medicine</u> , Academic Press, Inc., 239-253 (1985).
	THOMAS, "Marrow Transplantation for Malignant Diseases", <u>Journal of Clinical Oncology</u> , 1, 517-531 (1983).
	THOMAS et al., "Marrow Transplantation for Thalassemia", <u>Annals New York Academy of Sciences</u> , 445, 417-427 (1985).
	THOMAS, "MIRD Pamphlet No. 14: A Dynamic Urinary Bladder Model for Radiation Dose Calculations.", <u>Journal of Nuclear Medicine</u> , 33, 783-802 (1992). (Published erratum appears in <u>Journal of Nuclear Medicine</u> , 35, 73 (1994)).
	TURNER et al., "Radiopharmaceutical Therapy of 5T33 Murine Myeloma by Sequential Treatment with Samarium-153 Ethylenediaminetetramethylene Phosphonate, Melphalan, and Bone Marrow Transplantation", <u>Journal of the National Cancer Institute</u> , 85(18), 1508-1513 (1993).
	TURNER et al., "Samarium - 153 EDTMP Therapy of Disseminated Skeletal Metastasis", <u>Eur J. Nucl Med</u> , 15, 784-795 (1989).
	TURNER et al., "Samarium-153 EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation in the C57BL/KaWrij mouse as a model for treatment of multiple myeloma", <u>Australian & New Zealand J of Medicine</u> , 22, 405 (1992).
	TURNER et al., "Samarium-153 EDTMP and melphalan chemoradiotherapy regimen for bonemarrow ablation prior to marrow transplantation: an experimental model in the rat", <u>Nuclear Medicine Communications</u> , 13(5), 321-329 (1992).
RG	VOLKERT et al., "Characteristics of Tc-99m-Complexes of Large Tetraphosphonates", 1984 Abstract Form for Scientific Exhibits Society of Nuclear Medicine 31st Annual Meeting, Los Angeles, California, June 5-8, 1984.
RG	WEININGER, "Re-186 HEDP: A Potential Therapeutic Bone Agent", 24(5), Proceedings of the 30th Annual Meeting - Posters, P125. (year not available)
RG	WENDT, "An Improved Estimate of Activity in Skull-Like Structures", <u>Journal of Nuclear Medicine</u> , 42, Proceedings of the 48th Annual Meeting, 193P (2001).
RG	WENDT et al., "Correction of Scatter and Septal Penetration in Ho-166 Images to Enable Narrow Beam Attenuation Correction", <u>Journal of Nuclear Medicine</u> , 43(5), 221P-222P (2002).
RG	WINSTON, "Radioisotope Therapy In Bone and Joint Disease", <u>Seminars in Nuclear Medicine</u> , 9, 114-120 (1979).
RG	WISEMAN et al., "Bone Targeted Radioisotope Therapy for Treatment of Multiple Myeloma and Bone Tumors", <u>International Journal of Cancer</u> , 13, Abstract O 109, 104 (2002).

EXAMINER


D. Jones

DATE CONSIDERED

7/20/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/615,484
		Filing Date	July 08, 2003
		First Named Inventor	Fritzberg, Alan
		Group Art Unit	1614-1616
		Examiner Name	Unknown D. Jones
Sheet 10 of 10		Attorney Docket No: 295.034US1	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
RJ	WISEMAN et al., "Residual Whole Body 153Samarium Activity Predicts for Successful Autologous Peripheral Blood Progenitor Cell (PBPC) Engraftment Following High Dose 153Samarium Ethylene Diamine Tetramethylene Phosphonate (153Sm-EDTMP) Targeted Radiotherapy", <i>Blood</i> , 96, Abstract 1811, 421 (2000).
RJ	YOUNG et al., "High Dose Samarium-153 Ethylenediaminetetramethylene Phosphate (SM-153 EDTMP) in the Treatment of Bone Sarcomas", <i>The Journal of Nuclear Medicine</i> , 40(5), Proceedings of the 46th Annual Meeting, 219P (1999).
RJ	ZEEVAART et al., "Metal-ion Speciation in Blood Plasma Incorporating the Bisphosphonate, 1-hydroxy-4-aminopropylidenediphosphonate (APD), in Therapeutic Radiopharmaceuticals", <i>Journal of Inorganic Biochemistry</i> , 73, 265-272 (1999).


EXAMINER

D. Jones

DATE CONSIDERED

7/20/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Date line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	THERAPEUTIC AND DIAGNOSTIC COMPOUNDS, COMPOSITIONS, AND METHODS																						
<p>Application Number: 10/615484</p> <p>Confirmation Number: 8966</p> <p>First Named Applicant: Alan Fritzberg</p> <p>Attorney Docket Number: 295.034US1</p> <p>Art Unit: 1644 1616</p> <p>Examiner: Unknown Unknown D. Jones</p> <p>Search string: (3032584 or 3032585 or 3398198 or 3726912 or 3852414 or 3931396 or 3965254 or 3974268 or 3989730 or 4017596 or 4058704 or 4075314 or 4104366 or 4187284 or 4399817 or 4508625 or 4515767 or 4560548 or 4606907 or 4639365 or 4647447 or 4678667 or 4707353 or 4752464 or 4808541 or 4853209 or 4882142 or 4885363 or 4897254 or 4897255 or 4898724 or 4937333 or 4957939 or 4976950 or 5059412 or 5064633 or 5066478 or 5089249 or 5202109 or 5286497 or 5300279 or 5393512 or 5587451 or 5621001 or 5641803 or 5665761 or 5670537 or 5679318 or 5707610 or 5708169 or 5712275 or 5714467 or 5714504 or 5714604 or 5756472 or 5756505 or 5756685 or 5756725 or 5760063 or 5762907 or 5770617 or 5773421 or 5773443 or 5773696 or 5783570 or 5786325 or 5801172 or 5807854 or 5814634 or 5824698 or 5824874 or 5830855 or 5830889 or 5837253 or 5837726 or 5849956 or 5854213 or 5854280 or 5856347 or 5859032 or 5861430 or 5863773 or 5866549 or 5872249 or 5876738 or 5888526 or 5888941 or 5891890 or 5908862 or 5910498 or 5917084 or 5919438 or 5919925 or 6241961),pn.</p>																							
<p>US Patent Documents</p> <p>Note: Applicant is not required to submit a paper copy of cited US Patent Documents</p> <table border="1"><thead><tr><th>init</th><th>Cite.No.</th><th>Patent No.</th><th>Date</th><th>Patentee</th><th>Kind</th><th>Class</th><th>Subclass</th></tr></thead><tbody><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>								init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass								
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass																

1	3032584	1962-05-01	Bergel, , et al.	260	518
2	3032585	1962-05-01	Bergel, , et al.	260	518
3	3398198	1968-08-20	Kersnar, , et al.	260	584
4	3726912	1973-04-10	McCrary, , et al.	260	513.N
5	3852414	1974-12-03	Adler, , et al.	424	1
6	3931396	1976-01-06	Bardy, , et al.	424	1
7	3965254	1976-06-22	Tofe, , et al.	424	1
8	3974268	1976-08-10	Subramanian, , et al.	424	1
9	3989730	1976-11-02	Subramanian, , et al.	260	429.7
10	4017596	1977-04-12	Loberg, , et al.	424	1
11	4058704	1977-11-15	Shimizu,	219	528
12	4075314	1978-02-21	Wolfangel, , et al.	424	1
13	4104366	1978-08-01	Schmidt-Dunker, , et al.	424	1
14	4187284	1980-02-05	Rolleston, , et al.	424	1
15	4399817	1983-08-23	Benedict,	406	20
16	4508625	1985-04-02	Graham,	210	695
17	4515767	1985-05-07	Simon, , et al.	424	1.1
18	4560548	1985-12-24	Simon, , et al.	424	1.1
19	4606907	1986-08-19	Simon, , et al.	424	1.1
20	4639365	1987-01-27	Sherry,	424	9
21	4647447	1987-03-03	Gries, , et al.	424	9
22	4678667	1987-07-07	Meares, , et al.	424	85
23	4707353	1987-11-17	Bugaj, , et al.	424	1.11
24	4752464	1988-06-21	Lieberman, , et al.	424	1.1
25	4808541	1989-02-28	Mikola, , et al.	436	501
26	4853209	1989-08-01	Kaplan, , et al.	424	1.1
27	4882142	1989-11-21	Simon, , et al.	424	1.22
28	4885363	1989-12-05	Tweedle, , et al.	540	465
29	4897254	1990-01-30	Simon, , et al.	424	1.1
30	4897255	1990-01-30	Fritzberg, A. R., et al.	424	1.1
31	4898724	1990-02-06	Simon, , et al.	424	1.1
32	4937333	1990-06-26	Garlich, , et al.	540	474
33	4957939	1990-09-18	Gries, , et al.	514	492
34	4976950	1990-12-11	Simon, , et al.	424	1.1
35	5059412	1991-10-22	Simon, , et al.	424	1.1
36	5064633	1991-11-12	Simon, , et al.	424	1.1

7/20/04

37	5066478	1991-11-19	Simon, , et al.
38	5089249	1992-02-18	Fritzberg, , et al.
39	5202109	1993-04-13	Fritzberg, , et al.
40	5286497	1994-02-15	Hendrickson, , et al.
41	5300279	1994-04-05	Simon, , et al.
42	5393512	1995-02-28	Vanderheyden, , et al.
43	5587451	1996-12-24	Athey, , et al.
44	5621001	1997-04-15	Canetta, , et al.
45	5641803	1997-06-24	Canetta, , et al.
46	5665761	1997-09-09	Canetta, , et al.
47	5670537	1997-09-23	Canetta, , et al.
48	5679318	1997-10-21	Vanderheyden, , et al.
49	5707610	1998-01-13	Ibsen, , et al.
50	5708169	1998-01-13	Hester Jr., , et al.
51	5712275	1998-01-27	Van Gestel,
52	5714467	1998-02-03	Boman, , et al.
53	5714504	1998-02-03	Lindberg, , et al.
54	5714604	1998-02-03	Kiefer,
55	5756472	1998-05-26	Liesch, , et al.
56	5756505	1998-05-26	Nishino, , et al.
57	5756685	1998-05-26	Fritzberg, , et al.
58	5756725	1998-05-26	Wilkening, , et al.
59	5760063	1998-06-02	Lam, , et al.
60	5762907	1998-06-09	Simon, J. , et al.
61	5770617	1998-06-23	LaVoie, , et al.
62	5773421	1998-06-30	Alder, , et al.
63	5773443	1998-06-30	Ray, , et al.
64	5773696	1998-06-30	Liang, , et al.
65	5783570	1998-07-21	Yokota, , et al.
66	5786325	1998-07-28	Borromeo, , et al.
67	5801172	1998-09-01	Clapp-Shapiro, , et al.
68	5807854	1998-09-15	Bartoli, , et al.
69	5814634	1998-09-29	Nishino, , et al.
70	5824698	1998-10-20	Hasler, , et al.
71	5824874	1998-10-20	Ulbrich, , et al.
72	5830855	1998-11-03	Takemoto,

424	1.1
424	1.1
424	1.1
424	490
424	1.77
424	1.53
528	345
514	449
514	449
514	449
514	449
424	1.11
424	049
549	152
514	222.5
514	012
514	338
540	472
514	27
514	253
530	391.5
540	302
514	355
424	1.77
514	394
514	025
514	256
800	205
514	056
514	011
514	250
514	248
514	237.8
514	394
800	205
514	011

7/20/04

73	5830889	1998-11-03	Iwata, , et al.	514	195
74	5837253	1998-11-17	Cohen,	424	195.1
75	5837726	1998-11-17	Liu, , et al.	514	475
76	5849956	1998-12-15	Koga, , et al.	568	326
77	5854213	1998-12-29	Bouffard,	514	011
78	5854280	1998-12-29	Gomez, , et al.	514	456
79	5856347	1999-01-05	Hashiguchi, , et al.	514	390
80	5859032	1999-01-12	Nishino, , et al.	514	352
81	5861430	1999-01-19	Markonius,	514	456
82	5863773	1999-01-26	Gunawardana, , et al.	435	118
83	5866549	1999-02-02	Or, , et al.	514	029
84	5872249	1999-02-16	Park, , et al.	540	225
85	5876738	1999-03-02	Ohno, , et al.	424	404
86	5888526	1999-03-30	Tsubai, , et al.	424	405
87	5888941	1999-03-30	Bartoli, , et al.	504	262
88	5891890	1999-04-06	Nishino, , et al.	514	331
89	5908862	1999-06-01	Wai Lee, , et al.	514	546
90	5910498	1999-06-08	Yazaki, , et al.	514	255
91	5917084	1999-06-29	Jiang,	560	174
92	5919438	1999-07-06	Saint-Leger,	424	70.1
93	5919925	1999-07-06	Burton, , et al.	540	300
94	6241961	2001-06-05	Benes, , et al.	424	1.49

Signature

Examiner Name	Date
<i>R. Jones</i>	<i>7/20/04</i>



Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/615,484
Filing Date	July 8, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1618
Examiner Name	Jones, Dameron

Sheet 1 of 1

Attorney Docket No: 295.034US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
JS	US-2005/ 0129667A1	06/16/2005	Fritzberg, A. R., et al.	01/24/2005

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
---------------------	---------------------	------------------	---	----------------

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
---------------------	----------------------	---	----------------

EXAMINER

[Signature]


DATE CONSIDERED

10/24/05

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Sheet 1 of 1

Under the American Revolution Act of 1950, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/USPOA(10-01)
Approved for use through 12/31/2002, OMB 031-0001
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Complete if Known	
Application Number	10/615,484
Filing Date	July 8, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1616-1618
Examiner Name	Jones, Dameron
Attorney Docket No: 295.034US1	

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
JD	2005/0083905	03/24/2005	Fritzberg et al.	02/23/2004

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T *

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T *

EXAMINER


[Signature]

DATE CONSIDERED

5/13/05

Substitute Disclosure Statement Form (PTO-1448)
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional) * Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1448A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2003. OMB 051-0001
 US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	10/615,484
Filing Date	July 8, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1616 / 1618
Examiner Name	Jones, Dameron

Sheet 1 of 1

Attorney Docket No: 295.034US1

US PATENT DOCUMENTS

Examiner Initial*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
DA	US-2004/0126317 A1	07/01/2004	Fritzberg,	06/20/2003

class/sub

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
-------------------	---------------------	------------------	---	----------------


OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DA		PODOLOFF, D A., et al., "Phase I/II Studies of Holmium-166 DOTMP in Combination with Melphalan with or without Total Body Irradiation as a Preparative Regimen For Autologous Stem Cell Transplant (PBSCT) for Patients with Multiple Myeloma (MM)", <u>European Journal of Nuclear Medicine</u> , 26(9), Abstract No: PS-641, (1999), 1213	
DA		SRIVASTAVA, S C., et al., "Ruthenium-97 Labeled Compounds - A New Class of Radiopharmaceuticals", <u>Front. Nucl. Med., (Ser. Pap. Int. Congr. World Fed. Nucl. Med. Biol.)</u> , 2nd, EDITOR: Horst, Wolfgang (Ed), Wagner, Henry N., Jr. (Ed), Buchanan, Julia W (Ed), (1980), 123-133	
DA		WEININGER, J., "Re-186 HEDP: A Potential Therapeutic Bone Agent", <u>Journal of Nuclear Medicine</u> , 24(5), Proceedings of the 30th Annual Meeting - Posters, (1983), P125	

EXAMINER:

DATE CONSIDERED 5/13/05

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.



PTO/S2006A(10-01)
Approved for use through 10/1/2002, OAS 631-0031
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person shall be required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/615,484
	Filing Date	July 8, 2003
	First Named Inventor	Fritzberg, Alan
	Group Art Unit	1616/1618
	Examiner Name	D.L. Jones
Sheet 1 of 1		Attorney Docket No: 295.034US1

US PATENT DOCUMENTS						
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date if Appropriate
<i>[Signature]</i>	6,767,531	07/27/2004	Fritzberg et al.	424	1.65	12/11/01

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T*

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*

EXAMINER *[Signature]*

DATE CONSIDERED 5/13/05

Substitute Disclosure Statement Form (PTO-1448)
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) Applicant to place a check mark here if English language Translation is attached